AU1813901A - Chimeric flavivirus vaccines - Google Patents

Chimeric flavivirus vaccines

Info

Publication number
AU1813901A
AU1813901A AU18139/01A AU1813901A AU1813901A AU 1813901 A AU1813901 A AU 1813901A AU 18139/01 A AU18139/01 A AU 18139/01A AU 1813901 A AU1813901 A AU 1813901A AU 1813901 A AU1813901 A AU 1813901A
Authority
AU
Australia
Prior art keywords
chimeric flavivirus
flavivirus vaccines
vaccines
chimeric
flavivirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU18139/01A
Inventor
Thomas J. Chambers
Farshad Guirakhoo
Thomas P. Monath
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Biologics LLC
Original Assignee
OraVax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/452,638 external-priority patent/US6696281B1/en
Application filed by OraVax Inc filed Critical OraVax Inc
Publication of AU1813901A publication Critical patent/AU1813901A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/193—Equine encephalomyelitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AU18139/01A 1999-12-01 2000-12-01 Chimeric flavivirus vaccines Abandoned AU1813901A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/452,638 US6696281B1 (en) 1997-02-28 1999-12-01 Chimeric flavivirus vaccines
US09452638 1999-12-01
PCT/US2000/032821 WO2001039802A1 (en) 1999-12-01 2000-12-01 Chimeric flavivirus vaccines

Publications (1)

Publication Number Publication Date
AU1813901A true AU1813901A (en) 2001-06-12

Family

ID=23797288

Family Applications (1)

Application Number Title Priority Date Filing Date
AU18139/01A Abandoned AU1813901A (en) 1999-12-01 2000-12-01 Chimeric flavivirus vaccines

Country Status (2)

Country Link
AU (1) AU1813901A (en)
WO (1) WO2001039802A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425437B2 (en) 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
BR0210907A (en) 2001-06-01 2004-12-21 Acambis Inc Chimeric Flavivirus Vectors
US6682883B1 (en) 2001-07-19 2004-01-27 Acambis, Inc. Diagnosis of flavivirus infection
JP5164305B2 (en) 2001-10-19 2013-03-21 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー Methods for preventing and treating flavivirus infections in animals
US20040120964A1 (en) * 2001-10-29 2004-06-24 Mikszta John A. Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
NZ534159A (en) * 2002-01-15 2007-03-30 Acambis Inc Vaccines comprising flaviviruses with one or more hinge region mutations that reduce viscerotropism of the flaviviruses
DE60330708D1 (en) 2002-11-15 2010-02-04 Sanofi Pasteur Biologics Co VACCINE AGAINST WEST NILE VIRUS
EP1626708B1 (en) * 2003-05-23 2017-11-29 Novartis Vaccines and Diagnostics, Inc. Immunogenic reagents from west nile virus
EP1809325B1 (en) 2004-10-20 2013-11-20 Sanofi Pasteur Biologics, LLC Vaccines against japanese encephalitis virus
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
CN101090966B (en) 2004-12-24 2012-07-04 财团法人阪大微生物病研究会 Attenuated chimeric flavivirus bearing attenuated japanese encephalitis virus gene as backbone
US8124398B2 (en) 2005-04-24 2012-02-28 Sanofi Pasteur Biologics Co. Recombinant flavivirus vaccines
ATE507242T1 (en) 2005-05-12 2011-05-15 Crucell Holland Bv HOST CELL-SPECIFIC BINDING MOLECULES CAPABILITY OF NEUTRALIZING VIRUSES AND APPLICATIONS THEREOF
US20080193477A1 (en) * 2005-08-10 2008-08-14 Acambis Inc. Vaccination Against Dengue Virus Infection
BRPI0504945B8 (en) * 2005-10-31 2022-08-02 Fundacao Oswaldo Cruz METHOD FOR PRODUCTION OF RECOMBINANT FLAVIVIRUS CONTAINING NUCLEOTIDE SEQUENCES ENCODING A HETEROLOGOUS PROTEIN, DNA CONSTRUCT, FLAVIVIRUS, AND, VACCINE COMPOSITION TO IMMUNIZE AGAINST FLAVIVIRUS AND/OR OTHER PATHOGENS.
EP2043681B1 (en) 2006-07-14 2015-10-07 Sanofi Pasteur Biologics, LLC Construction of recombinant virus vaccines by direct transposon-mediated insertion of foreign immunologic determinants into vector virus proteins
BRPI0718548A2 (en) 2006-11-07 2013-11-12 Sanofi Pasteur Biologics Co LABORIZATION OF VACCINE STABILIZATION
WO2008100464A1 (en) * 2007-02-09 2008-08-21 Sanofi Pasteur Biologics Co. Viral vectors and methods of use
CN102906266A (en) 2010-05-21 2013-01-30 高等教育联邦系统-匹兹堡大学 Universal dengue virus sequences and methods of use
JP6818548B2 (en) * 2013-03-15 2021-01-20 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. Compositions and Methods for Dengue Virus Chimeric Constructs in Vaccines
TW201620546A (en) 2014-09-02 2016-06-16 賽諾菲巴斯德公司 Vaccine compositions
EP3316905A1 (en) 2015-07-03 2018-05-09 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
GB201704126D0 (en) * 2017-03-15 2017-04-26 Blom Nihlén Kim Andrea Vaccine
JP7313345B2 (en) 2017-10-05 2023-07-24 サノフィ・パスツール Composition for booster vaccination against dengue fever
GB201716222D0 (en) * 2017-10-05 2017-11-22 Univ Leuven Kath Chimeric Flavivirus Vaccines
GB201716307D0 (en) * 2017-10-05 2017-11-22 Univ Leuven Kath Chimeric yellow fever zika virus strain

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228705B1 (en) * 1997-02-28 2013-05-28 Univ St Louis Chimeric flavivirus vaccines

Also Published As

Publication number Publication date
WO2001039802A9 (en) 2002-05-16
WO2001039802A1 (en) 2001-06-07

Similar Documents

Publication Publication Date Title
AU1813901A (en) Chimeric flavivirus vaccines
HUP0002139A3 (en) Chimeric flavivirus vaccines
HUP0202885A3 (en) Vaccines
EP1385538A4 (en) Chimeric vaccines
IL145044A0 (en) Vaccine
HUS1300072I1 (en) Vaccine
AU2919001A (en) Syringe
AU2001274548A1 (en) Syringe
AU6600300A (en) Pneumococcal vaccines
AU5977700A (en) Vaccines
GB9901254D0 (en) Vaccines
AU1541601A (en) Syringes
AU6158700A (en) Vaccine
AU2002222139A1 (en) Hcv vaccines
AU6983000A (en) Chimeric proteins
GB9906437D0 (en) Vaccine
AU5811600A (en) Vaccine
AU5084300A (en) New vaccine formulations - 1
AU4351900A (en) Inducible vaccines
AU4935700A (en) New vaccine formulations-3
GB9909072D0 (en) Vaccine
GB9909466D0 (en) Vaccines
GB9904280D0 (en) Vaccines
GB9904048D0 (en) Vaccines
AUPQ813700A0 (en) Syringe

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase